80 results about "Guaifenesin" patented technology

Pharmaceutical compositions are provided containing a combination of benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof. Methods of using compositions comprising benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof, provide relief from cough, pulmonary congestion or both. The compositions and methods provide relief to opiate-sensitive individuals, in particular, as well as to infants and other pediatric patients.

The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.

Topical pharmaceutical formulations and compositions for transdermal delivery of a variety of active agents are described. The formulations and compositions are formulated to provide a long lasting effect of the agent being delivered. The formulations and compositions of the present invention contain a transdermal vehicle and an adrenergic drug. The formulations and compositions may also contain guaifenesin.

The present invention relates to compositions comprising an antitussive, a decongestant and an expectorant, and in a specific embodiment comprising hydrocodone, phenylephrine hydrochloride and guaifenesin, wherein the composition may be substantially free of added sugar and added alcohol, and methods for using these compositions for the treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.

The present invention relates to compositions that comprise an expectorant, an extended release antitussive, and an extended release decongestant, in liquid. Specifically, the compositions may comprise guaifenesin, and the tannate salts of phenylephrine and dextromethorphan. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.

The present invention relates to compositions that comprise immediate release and extended release guaifenesin, extended release phenylephrine and immediate and extended release dextromethorphan. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.

The invention provides a method for six active components in a drug sample. In the method, the six active components comprise paracetamol, phenylephrine hydrochloride, doxylamine succinate, dextromethorphan hydrobromide, guaifenesin and chlorpheniramine maleate; the method uses high performance liquid chromatography (HPLC) to detect the drug sample, wherein the mobile phase of HPLC comprises a mobile phase A which is an aqueous solution containing trifluoroacetic acid of which the concentration is 0.1v/v% and a mobile phase B which is a mixed solution of acetonitrile and methanol in a volume ratio of 60: 40. The detection method provided by the invention can simply and quickly detect the six active components in the drug sample simultaneously, and the six active components can be separatedeffectively, and the detection method is simply operated, and quickly analyzed, suitable for detection of most cold medicines and wide in detection application range.

The invention relates to a method for producing lignan slow-release micro drop and relative preparation, wherein it comprises active component, and carrier element, slow-release package and quick-release drug layer. The invention uses round technique to prepare high-carrier drug element to be packed and coated with quick-release layer; the slow-release layer uses cellulose ethyl ether; package is processed at fluid condition. The invention can release drug for 12h.

The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.

The present invention relates to a kind of medicine composition for treating productive cough, and the medicine composition has ambroxol hydrochloride, guaifenesin and levosalbutamol in certain weight proportion and pharmaceutically acceptable supplementary material. The medicine composition may be prepared into pharmaceutically acceptable preparation forms for treating productive cough caused by chronic bronchitis, asthma, repeatable lower respiratory infection and other respiratory system diseases.

The invention discloses a composite solid base catalyst which is mainly prepared from the following components in parts by mass: 100 parts of gamma-Al2O3 as a carrier, 0.5-5 parts of a binding agent as a loaded component, 1-25 parts of a magnesium-containing compound, 1-25 parts of a calcium-containing compound, 0.5-5 parts of polyacrylamide and 0.1-2 parts of inorganic base, wherein the binding agent is selected from one of glycerol, starch, methylcellulose, polypropylene glycol, alumina sol and sodium silicate; the magnesium-containing compound is selected from one of MgO, Mg(OH)2, Mg(CO3)2, Mg(OAc)2 and MgCl2; the calcium-containing compound is selected from one of CaO, Ca(OH)2, Ca(CO3)2 and CaCl2; the inorganic base is selected from one of NaOH, KOH, Na2CO3 and K2CO3. The catalyst is used for preparing guaifenesin, is simple and convenient to operate, environmentally friendly, low in energy consumption and high in yield.

The present invention discloses an oral solid preparation containing ambroxal hydrochloride and guaifenesin active components. It is made up by using ambroxol hydrochloride and guaifenesin as active components and auxiliary material according to a certain ratio through a certain preparation process. Said oral solid preparation can be used for mainly curing the diseases of chronic bronchitis and periodic lower respiratory tract infection.

The invention discloses a method for analyzing daytime severe cold and flu capsules by high performance liquid chromatography. The daytime severe cold and flu capsules contain acetaminophen, phenylephrine hydrochloride, dextromethorphan hydrobromide and guaifenesin; high performance liquid chromatography analysis conditions are as follows: a chromatographic column adopts an octadecyl silane bonded silica gel column, a sodium octanesulfonate containing 0.1v% triethylamine is used as a mobile phase A, and acetonitrile is used as a mobile phase B. The method can efficiently and simultaneously detect four effective components in the daytime severe cold and flu capsules; furthermore, the method is easy to operate, high in analysis speed, high in repetitiveness and extremely high in specificity; the product quality of a daytime severe cold and flu capsule preparation can be relatively efficiently and comprehensively controlled.

A topical liposomal base delivery agent for physiologically enhancing muscle efficiency and relaxation, which combines the physiological effects of guaifenesin, magnesium, and methylsulfonylmethane. The resulting physiological reaction reduces muscle and joint soreness in the host. The present invention is an improvement over existing methods that deliver magnesium to muscle tissue.

The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The present invention also relates to a process for the preparation of extended release formulations comprising guaifenesin.

The invention provides a compound dextromethorphan hydrobromide syrup and a preparation method for the same. The compound dextromethorphan hydrobromide syrup is used for eliminating phlegm in cough, and comprises dextromethorphan hydrobromide, guaifenesin and a bacillus natto extract. The syrup improves the safety of medication and is especially suitable for children, reduces bitter taste and the consumption of a flavouring agent, improves the stability, especially the colour of solution and the stability of the colour, and improves the curative effect on the cough caused by cold and bronchitis simultaneously.

The present invention relates to compositions that comprise immediate release and extended release guaifenesin, and extended release hydrocodone bitartrate. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.

The invention relates to a countercurrent continuous chromatographic resolution method of a guaifenesin racemate. The method utilizes simulated moving bed chromatography to realize continuous separation and comprises one or more of a synchronous control process (SMB), an asynchronous control process (Varicol), a feed rate periodic change process (Powerfeed) and a feed concentration periodic change process (Modicon). When silica gel coated with cellulose-tris(3, 5-dimethylphenylcarbamate) is used as a chiral stationary phase and a mixture of n-hexane and ethanol is used as a mobile phase, the method can continuously and efficiently resolve a guaifenesin racemate, acquire a R-guaifenesin racemate enantiomer and a S-guaifenesin racemate enantiomer with high purity (greater than 99%) and meet the pharmaceutical market standards. The method has a high degree of production automation, high production efficiency and simple processes. In the whole process, the solvent can be recycled so that a cost is low and pollution is avoided.

The invention relates to a drug combination for relieving cough and reducing phlegm, which is composed of active constituents and a pharmaceutic adjuvant, wherein the active constituents comprise butamirate critrate, dextromethorphan hydrobromide and guaifenesin. The composition can be prepared into various kinds of oral preparations such as granules, troches, capsules, oral solution, syrup and the like and can be used for carrying out symptomatic treatment on related diseases with symptoms of cough, abundance of phlegm and the like.

The invention discloses a novel environment-friendly flame-retardant finishing agent. The novel environment-friendly flame-retardant finishing agent is prepared from, by weight, 20-30 parts of glycerophosphate, 10-25 parts of ethylene glycol monostearate, 5-11 parts of ammonium acetate, 8-12 parts of hydroxymethyl cellulose, 3-7 parts of chitosan, 4-9 parts of potassium xylenesulphonate, 11-22 parts of guaifenesin, 6-12 parts of ethoxymethylenmalonic acid diethylester, 2-7 parts of 3-(2-aminoethylamino)propyl-dimethoxymethylsilane and 15-25 parts of sorbitol. The flame-retardant level and flame-retardant property of the finishing agent can be significantly improved, and the finishing agent is environmentally friendly, free of pollution and friendly to the environment.

Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of a cold medication which consists essentially of combinations of a nonsedating or minimally sedating antihistamines with pain relievers and the expectorant, guaifenesin.

The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and pseudoephedrine. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises pseudoephedrine. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.

The invention relates to a liquid composition containing phenylephrine hydrochloride as well as a preparation and application thereof. The composition comprises three compositions: the first is a combination of the phenylephrine hydrochloride, choline salicylic acid and guaifenesin; the second is a combination of the phenylephrine hydrochloride, acetaminophen and pheniramine maleate; and the thirdis a combination of the phenylephrine hydrochloride, the acetaminophen, dextromethorphan hydrobromide and doxylamine succinate. The composition disclosed by the invention can be prepared into a liquid preparation, and a preferable dosage form is suspension.

The invention provides a drug composition with the active components of levodropropizine, guaifenesin and pseudoephedrine or acceptable salts on the drugs and a preparation method, which is used for treating nasopharynx mucosa hyperemia, nasal obstruction, sneeze, snivel caused by cold and other diseases, cough and expectoration and other symptoms caused by bronchitis. Compared with the common used centrally antitussive drugs on market, the peripherally antitussive drugs of levodropropizine adopted by the invention have the advantages of obvious antitussive effect and less adverse reaction.